These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 35586953

  • 1. Speed of onset of a new chewable formulation of oclacitinib maleate (Apoquel®) in a canine model of IL-31-induced pruritus.
    Fleck T, Norris L, King V, Lesman S, Gonzales AJ.
    J Vet Pharmacol Ther; 2022 Jul; 45(4):380-384. PubMed ID: 35586953
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis.
    Cosgrove SB, Wren JA, Cleaver DM, Walsh KF, Follis SI, King VI, Tena JK, Stegemann MR.
    Vet Dermatol; 2013 Dec; 24(6):587-97, e141-2. PubMed ID: 24581322
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. IL-31-induced pruritus in dogs: a novel experimental model to evaluate anti-pruritic effects of canine therapeutics.
    Gonzales AJ, Fleck TJ, Humphrey WR, Galvan BA, Aleo MM, Mahabir SP, Tena JK, Greenwood KG, McCall RB.
    Vet Dermatol; 2016 Feb; 27(1):34-e10. PubMed ID: 26666963
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Immunomodulatory effect of long-term oclacitinib maleate therapy in dogs with atopic dermatitis.
    De Caro Martins G, da Costa-Val AP, Coura FM, Diamantino GML, Nogueira MM, de Oliveira Melo-Junior OA, Giunchetti RC, da Silveira-Lemos D, Melo MM.
    Vet Dermatol; 2022 Apr; 33(2):142-e40. PubMed ID: 34747068
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs.
    Schäfer L, Thom N.
    Vet Dermatol; 2024 Aug; 35(4):408-417. PubMed ID: 38465482
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study.
    Simpson AC, Schissler JR, Rosychuk RAW, Moore AR.
    Vet Dermatol; 2017 Oct; 28(5):485-e113. PubMed ID: 28513001
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A double-blinded, randomized, methylprednisolone-controlled study on the efficacy of oclacitinib in the management of pruritus in cats with nonflea nonfood-induced hypersensitivity dermatitis.
    Noli C, Matricoti I, Schievano C.
    Vet Dermatol; 2019 Apr; 30(2):110-e30. PubMed ID: 30656750
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.